Answers are grounded in this paper and cite their sources.
Hormone therapies in prostate cancer (PC) patients aims to decrease androgen levels or block androgen action so as to inhibit the growth in PCs, which are therefore called castrate-sensitive PC. However, it is reported that most PCs eventually stop responding to hormone therapy and become castration (or castrate) resistant. Besides this, the exorbitant cost of hormonal therapy (HT) leads to financial toxicity which is reported to have been widely prevalent among cancer survivors and negatively impacting quality of life (QoL) and survival. The present case study describes the potential of Ayurveda Rasayana therapy (ART) in the management of metastatic PC who stopped because of financial constraints. With widespread skeletal metastases, this 75-year-old man with stage IV B PC shifted from HT to Rasayana therapy because of financial constraints. Following Rasayana therapy, the patient reported therapeutic improvements, such as drop in prostate-specific antigen levels from 25.153 ng/mL to 4.170 ng/mL and the alleviation of symptoms such as lower limb pain, back discomfort, and urological problems. Decrease in bone metastases was observed in imaging investigations. The FACT-G and ECOG scales showed an improvement in the patient’s QoL, and no side effects were reported.
No takes yet. Share an insight, caveat, or question.
Bendale et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: